In this webinar Dr. Massimo Cristofanilli, Associate Director of Translational Research and Precision Medicine at Robert Lurie Cancer Center, Northwestern University, will review the evidence, as well as clinical case studies demonstrating how CTCs can be utilized in clinical practice and clinical research studies in metastatic breast cancer.
In a recent interview with ANSA, the CEO of the Menarini Group, Elcin Barker Ergun commented: “As we go through one of the biggest health challenges in this century, Menarini Group continues to be a key actor in the fight against the pandemic by bringing crucial Covid-19 tests to market and recently extending into therapeutic solutions, joining forces with Tuscany Life Sciences to bring an antibody against Covid-19.
We must also do everything possible to anticipate and prevent other crises such as the key threat from AMR where if not acted in a decisive way today, can turn into an even larger crisis than Covid-19 in coming years.”
Dr. Massimo Cristofanilli, MD of the Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL discusses the use of liquid biopsy diagnostics as objective and measurable tools to evaluate the dynamic changes of Metastatic Breast Cancer (MBC) .
Dr. Matija SNUDERL, from NYU Langone Health, presents his research using the DEPArray cell sorting system to isolate pure cells from archived FFPE samples
Single Cell Forensics
Dr. Katja ANSLINGER, from Ludwig-Maximilians-University of Munich, discusses her latest findings in the field of single-cell forensics
Discover the new VRNxT™, a volume reduction instrument optimized to remove manual sample volume reduction steps in cellular biology workflows
DEPArray technology overview